This stock is no longer traded. It was delisted on August 13, 2026. Prices stop on that date; discussion is still counted.
No summary has been written for this.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about DRMAW also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Dermata Therapeutics Holdings Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel pharmaceutical products. Its primary focus is on treating medical dermatological conditions with significant market needs. The company's distinctive approach involves leveraging its proprietary platform targeting both inflammatory mechanisms and tissue remodeling, leading to potential therapeutic breakthroughs. Dermata's pipeline includes innovative treatments for a variety of skin disorders, designed to offer improved efficacy over existing solutions. Through strategic partnerships and ongoing clinical research, Dermata aims to address challenging diseases like psoriasis and acne, which impact millions worldwide. Its commitment to innovation positions it as a significant player in the biotechnology industry, potentially transforming the dermatological treatment landscape.
Website3525 Del Mar Heights Rd.
San Diego, CA, 92130
United States
The latest articles about DRMAW.
Real-time index price for TSX Venture Composite Index (JX), along with buy or sell indicators, analysis, charts, historical performance, news and more